Physician profile
Arman Janloo
NPI 1710169446
$1,252.58
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.68 · 2021: $401 · 2022: $790 · 2024: $48.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.28 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.86 | 2021-2022 | |
| Lilly USA, LLC | $95.59 | 2021-2022 | |
| Glaxosmithkline, LLC. | $87.01 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $82.27 | 2021 | |
| Pfizer INC. | $68.76 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.13 | 2022 | |
| Sunovion Pharmaceuticals INC. | $42.54 | 2021-2022 | |
| Novo Nordisk INC | $40.13 | 2021-2022 | |
| Esperion Therapeutics, INC. | $38.94 | 2021 | |
| Amarin Pharma, INC. | $36.76 | 2022 | |
| Astellas Pharma US INC | $31.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.68 | 2021 | |
| Merck Sharp & Dohme LLC | $24.92 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $19.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.45 | 2022 | |
| Horizon Therapeutics Plc | $18.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.03 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arman Janloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.